KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Amortization of Deferred Charges (2017 - 2025)

Historic Amortization of Deferred Charges for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $2.7 million.

  • Aquestive Therapeutics' Amortization of Deferred Charges rose 280.58% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 1206.1%. This contributed to the annual value of $10.7 million for FY2024, which is 44330.63% up from last year.
  • Aquestive Therapeutics' Amortization of Deferred Charges amounted to $2.7 million in Q3 2025, which was up 280.58% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Amortization of Deferred Charges peaked at $2.8 million during Q1 2025, and registered a low of $40000.0 during Q1 2022.
  • In the last 5 years, Aquestive Therapeutics' Amortization of Deferred Charges had a median value of $1.2 million in 2021 and averaged $1.5 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Amortization of Deferred Charges tumbled by 9662.16% in 2022, and later skyrocketed by 292068.97% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Amortization of Deferred Charges (Quarter) stood at $127000.0 in 2021, then crashed by 54.33% to $58000.0 in 2022, then skyrocketed by 2920.69% to $1.8 million in 2023, then soared by 54.05% to $2.7 million in 2024, then increased by 1.82% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.8 million during Q1 2025.